patented technology to grow and expand adult Stem Cells
Adult stem cell development company commencing clinical trials applicable to estimated $30 billion degenerative disease market place
Message: fwiw
Pluristem Therapeutics beats by $0.02, revenue in-line
Nov 9 2015, 08:41 ET | About: Pluristem Therapeutics, Inc. (PSTI) | By: Mamta Mayani, SA News Editor 
Pluristem Therapeutics (NASDAQ:PSTI): FQ1 EPS of -$0.07 beats by $0.02.
Revenue of $0.1M in-line (flat Y/Y).
New Message
Please
login
to post a reply